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Abstract Osteocytes establish an extensive intracellular and
extracellular communication system via gap-junction-coupled
cell processes and canaliculi throughout bone and the com-
munication system is extended to osteoblasts on the bone
surface. The osteocyte network is an ideal mechanosensory
system and suitable for mechanotransduction. However, the
overall function of the osteocyte network remains to be clari-
fied, since bone resorption is enhanced by osteocyte apoptosis,
which is followed by a process of secondary necrosis attribut-
able to the lack of scavengers. The enhanced bone resorption is
caused by the release of intracellular content, including immu-
nostimulatory molecules that activate osteoclastogenesis
through the canaliculi. Therefore, a mouse model is required
in which the osteocyte network is disrupted but in which no
bone resorption is induced, in order to evaluate the overall
functions of the osteocyte network. One such model is the
BCL2 transgenic mouse, in which the osteocyte network,
including both intracellular and extracellular networks, is dis-
rupted. Another model is the osteocyte-specificGja1 knockout
mouse, in which intercellular communication through gap
junctions is impaired but the canalicular system is intact.
Combining the findings from these mouse models with previ-
ous histological observations showing the inverse linkage be-
tween osteocyte density and bone formation, we conclude that
the osteocyte network enhances bone resorption and inhibits
bone formation under physiological conditions. Further, studies
with BCL2 transgenic mice show that these osteocyte functions
are augmented in the unloaded condition. In this condition,
Rankl upregulation in osteoblasts and Sost upregulation in
osteocytes are, at least in part, responsible for enhanced bone
resorption and suppressed bone formation, respectively.
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Introduction
Osteocytes, which are embedded in the bone matrix, estab-
lish an extensive intracellular and extracellular communica-
tion system via gap-junction-coupled cell processes and
canaliculi through which cell processes pass throughout
the bone and the communication system is extended to
osteoblasts on the bone surface (Marks and Odgren 2002).
Bone tissue is able to adapt its mass and three-dimensional
structure to the prevailing mechanical usage to achieve
higher load-bearing efficiency (Wolff 1892). The lacunoca-
nalicular network formed by osteocytes is thought to be an
ideal mechanosensory system and suitable for mechano-
transduction by which mechanical energy is converted into
electrical and/or biochemical signals (Burger and Klein-
Nulend 1999; Martin 2000; Ehrlich and Lanyon 2002;
Knothe Tate 2003; Bonewald and Johnson 2008; Noble
2008). However, the special anatomic features of osteocytes,
which are isolated in lacunae but are three-dimensionally
connected to each other, make it difficult to study their
function. This review focuses on the mechanism of osteo-
cyte apoptosis-induced bone resorption and functions of the
osteocyte network in the regulation of bone mass under
physiological and unloaded conditions.
Osteocyte death and bone remodeling
Osteocyte death occurs during aging, after menopause, at
unloading and under pathological conditions such as micro-
cracks and the death of osteocytes is closely coupled with
bone resorption (Noble and Reeve 2000; Cardoso et al.
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2009; Emerton et al. 2010). Cells die mainly through one of
three pathways, i.e., apoptosis, autophagic cell death and
necrosis, under physiological and pathological conditions,
although dying cells can share apoptotic and autophagic
features (Bursch 2001; Fig. 1). If cells die through apoptosis
or autophagy, death is completed with the removal of the
cells through engulfment by scavengers. In these cases, the
cells are quietly removed without inflammation, because the
integrity of the cytoplasmic membranes is maintained when
phagocytosis occurs. In contrast, strong insults cause bioen-
ergetic failure and rapid loss of the integrity of the cytoplas-
mic membrane, both of which are core events of necrosis.
Necrosis leads to the rupture of the cytoplasmic membrane
and most of the intracellular content is released into the
extracellular environment. The released intracellular content
encompasses immunostimulatory molecules including the
so-called damage-associated molecular pattern molecules,
such as S100 family molecules, high-mobility group box 1
protein, purine metabolites, heat-shock proteins and uric
acid (Lotze and Tracey 2005; Zong and Thompson 2006).
The release of the immunostimulatory molecules actively
recruits a defensive or a reparative response to the damaged
regions. If cells at the terminal phase of apoptosis or auto-
phagic cell death are not engulfed by phagocytes, a transi-
tion to necrosis ensues and the cells are eliminated by cell
disruption. This process is called secondary necrosis (Majno
and Joris 1995; Silva et al. 2008). As scavengers cannot
reach osteocytes, any type of osteocyte death will end in the
rupture of the cytoplasmic membrane. After cell rupture,
immunostimulatory molecules are released from lacunae
through canaliculi to the bone surface and vascular channels
and facilitate the recruitment and activation of macrophages,
thereby promoting the production of proinflammatory cyto-
kines, including tumor necrosis factor-α (TNF-α), interleukin
(IL)-6 and IL-1 (Lotze and Tracey 2005). Further, IL-6 and
IL-1 induce receptor activator of nuclear factor κ-B ligand
(Rankl) expression, which is essential for osteoclastogenesis
(Yasuda et al. 1998; Kong et al. 1999; O’Brien 2010). As
TNF-α, IL-6 and IL-1 are the most important proinflamma-
tory cytokines triggering inflammatory bone loss (Firestein
2003), primary and secondary osteocyte necrosis could lead to
the enhancement of osteoclastogenesis and bone resorption,
which comprise a repair process in bone (Fig. 1).
Apoptotic osteocytes show enhancement of osteoclasto-
genesis in vitro (Kogianni et al. 2008; Al-Dujaili et al. 2011;
Cheung et al. 2012; Shandala et al. 2012). Addition of
apoptotic bodies from osteocytes but not osteoblasts induces
osteoclastogenesis through the induction of TNF-α produc-
tion by mononuclear osteoclast precursors (Kogianni et al.
2008). Conditioned medium from apoptotic osteocytic cell
line MLO-Y4 contains more soluble Rankl than that from
non-apoptotic MLO-Y4 cells and induces osteoclastogene-
sis (Al-Dujaili et al. 2011). Methotrexate (MTX)-induced
apoptosis of MLO-Y4 cells increases IL-6 and IL-11
Fig. 1 Osteocyte death and bone resorption. Cells die mainly through
one of three pathways: apoptosis, autophagic cell death and necrosis.
As osteocytes at the terminal phase of apoptosis or autophagic cell
death are not engulfed by phagocytes, the process of secondary necro-
sis ensues. After cell rupture, immunostimulatory molecules including
high-mobility group box 1 (HMGB1), S100, heat shock protein (HSP),
adenosine triphosphate (ATP) and uric acid are released from lacunae
through canaliculi to the bone surface and vascular channels, where
they facilitate the recruitment and activation of macrophages, thereby
promoting the production of proinflammatory cytokines, including
tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6) and interleukin
1 (IL-1), which induce osteoclastogenesis and bone resorption. Apo-
ptotic osteocytes release osteoclastogenesis-promoting factors, includ-
ing soluble receptor activator of nuclear factor κ-B ligand (sRankl), IL-
6 and soluble IL-6 receptor (sIL-6R) and induce TNF-α expression in
osteoclast precursors in vitro
192 Cell Tissue Res (2013) 352:191–198
expression and the conditioned media promote osteo-
clastogenesis (Shandala et al. 2012). Further, apoptotic
MLO-Y4-conditioned media promote osteoclast precursor
adhesion to endothelial cells via intercellular adhesion mole-
cule 1 (ICAM-1), probably through the induction of IL-6 and
soluble IL-6 receptor (Cheung et al. 2012). Therefore,
apoptotic osteocytes can upregulate the expression of
osteoclastogenesis-promoting factors (Fig. 1).
Another special feature of osteocyte death is the sustained
detection of degraded DNA by terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL;
Weinstein et al. 2000; Moriishi et al. 2011, 2012). This indi-
cates that a part of the DNA degraded during the process of
apoptosis is retained in the lacunae, even after secondary
necrosis. Even during primary necrosis, randomly degraded
DNA retained in the lacunae can be detected by TUNEL. The
reactivity of TUNEL in the lacunae is retained until the bone,
including the lacunae, is resorbed.
Functions of osteocytes in bone resorption
As the death of osteocytes induces bone resorption, the
physiological function of osteocytes has been considered
to be the inhibition of bone resorption (Gu et al. 2005;
Tatsumi et al. 2007). A typical example is osteocyte ablation
by diphtheria toxin (Tatsumi et al. 2007). Transgenic mice
expressing diphtheria toxin receptor under the control of the
dentin matrix protein 1 (Dmp1) promoter show enhanced
bone resorption resulting in severe osteoporosis after the
injection of diphtheria toxin. Dmp1 expression begins in
osteoblasts when they are about to be embedded into the bone
matrix and Dmp1 expression is high in immature osteocytes
but decreases during osteocyte maturation (Toyosawa et al.
2001; Xiong et al. 2011). After primary or secondary necro-
sis caused by diphtheria toxin, the intracellular content of
osteocytes is released from the lacunae onto the bone sur-
face and vascular channels and promotes osteoclastogenesis
as a process of repair (Fig. 1). This seems to be the case,
because Rankl is highly induced after the injection of diph-
theria toxin (Tatsumi et al. 2007). Although osteocyte death
causes bone resorption, whether live osteocytes inhibit bone
resorption remains unclear.
Gja1 (connexin 43) is the major gap junction protein and
plays important roles in osteogenesis and osteoblast func-
tion (Lecanda et al. 2000; Chung et al. 2006; Watkins et al.
2011). Targeted deletion of Gja1 in osteocytes results in the
disruption of the intercellular communication of osteocytes
through gap junctions, while retaining communication
through the canalicular network (Bivi et al. 2012). In this
mouse model, osteocyte apoptosis is increased, the osteoclast
number and surface are increased at the endocortical sur-
face and the marrow cavity is enlarged. This indicates that
osteocyte apoptosis in conditional Gja1 knockout mice
could induce bone resorption, probably because the intra-
cellular content of dead osteocytes could be released
through the intact canalicular network and trigger osteoclas-
togenesis and bone resorption (Fig. 1). The abundance of
osteoclast precursor cells and immune cells in bone marrow
should facilitate bone resorption at the endocortical surface
after osteocyte apoptosis.
Another model of dysfunction of the osteocyte network is
the osteoblast-specific BCL2 transgenic mouse. BCL2 trans-
genic mice have a reduced number of osteocyte processes
probably because of the function of BCL2 to alter cytoskel-
etal organization; the osteocytes gradually die by apoptosis
and the frequency of TUNEL-positive lacunae reaches 80%
at 4 months of age (Moriishi et al. 2011, 2012). However,
bone resorption is not induced by osteocyte apoptosis in
BCL2 transgenic mice and both the intracellular and extra-
cellular osteocyte networks are disrupted at 4 months of age
by the reduced number of canaliculi and the accumulation of
TUNEL-positive lacunae. The absence of enhanced bone
resorption in BCL2 transgenic mice seems to be attributable
to the failure of canalicular (extracellular) network forma-
tion, which interrupts the release of the intracellular content
of dead osteocytes onto the bone surface and into vascular
channels. Contrary to many previous observations that os-
teocyte apoptosis enhances bone resorption, the number of
osteoclasts and bone resorption are reduced in BCL2 trans-
genic mice. Interestingly, the number of osteoclasts is re-
duced on the endocortical surface but not on the periosteal
surface in cortical bone, suggesting that the osteocyte net-
work plays a major role in regulating osteoclastogenesis on
the endocortical surface of cortical bone. These findings
indicate that the disruption of both the intercellular and
extracellular communication systems of osteocytes sup-
presses osteoclastogenesis and bone resorption. As BCL2
overexpression in osteoblasts has no effect on osteoclasto-
genesis and bone resorption (Moriishi et al. 2011, 2012), we
conclude that the osteocyte network enhances osteoclasto-
genesis and bone resorption under physiological conditions
(Fig. 2).
Osteocytes highly express Rankl compared with osteo-
blasts (Nakashima et al. 2011; Xiong et al. 2011; Moriishi et
al. 2012). Conditional Rankl deletion by using Dmp1 Cre
transgenic mice results in increased bone mass (Nakashima
et al. 2011; Xiong et al. 2011). Rankl is produced as a
membrane-bound or soluble form, although the membrane-
bound form is much more efficient in terms of osteoclast
formation than the soluble form (Lum et al. 1999; Nakashima
et al. 2000; Ikeda et al. 2001; Hikita et al. 2006). The produc-
tion of soluble Rankl (sRankl) in MLO-Y4 cells is controver-
sial; one study has shown that the conditioned media from
MLO-Y4 cells support osteoclastogenesis, whereas another
has demonstrated that conditioned media fail to support
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osteoclastogenesis (Zhao et al. 2002; Al-Dujaili et al. 2011).
As sRankl is detected in the circulatory system of humans
(Schett et al. 2004; Trofimov et al. 2004; Rogers and Eastell
2005; Ziegler et al. 2005), the physiological importance of
sRankl produced by osteocytes needs to be investigated,
because the direct interaction of osteocytes with osteoclasts
and their precursors will be limited (Fig. 2). The secreted
factor osteoprotegerin (Opg), which is produced in osteocytes,
might also be released onto the bone surface and vascular
channel through canaliculi without being trapped by the Rankl
on the surface of osteocytes in the Rankl conditional knockout
mice, because Opg is also highly expressed in osteocytes
(Moriishi et al. 2012). Under physiological conditions, most
of the Opg produced by osteocytes seem to be trapped by
Rankl on the surface of osteocytes, because the osteocyte
network enhances osteoclastogenesis under physiological
conditions (Moriishi et al. 2012; Fig. 2).
Functions of osteocytes in bone formation
The function of osteocytes in bone formation under physi-
ological conditions has been controversial. Ablation of
osteocytes by diphtheria toxin severely reduces bone forma-
tion, indicating that osteocyte death also affects bone
formation. Reduced bone formation also seems to be caused
by secondary necrosis-induced inflammation, because oste-
oblast maturation is severely inhibited in diphtheria toxin
receptor transgenic mice (Tatsumi et al. 2007). In contrast,
osteocyte density is negatively correlated with bone forma-
tion and both the empty lacunar density and periosteal bone
apposition increase with age, suggesting a linkage between
the two phenomena (Lazenby 1990; Qiu et al. 2002; Metz et
al. 2003; Russo et al. 2006; Hedgecock et al. 2007).
Mice carrying a targeted mutation of Col1a1, encoding a
collagenase-resistant form of type I collagen, exhibit osteocyte
apoptosis and increased bone formation (Zhao et al. 2000).
Further, enhanced bone formation at the periosteal and
endocortical surfaces is localized in the area in which
viable osteocytes are lost in osteocyte-specificGja1 knockout
mice (Bivi et al. 2012). In a study of BCL2 transgenic mice at
4 months of age, bone formation in both trabecular and
cortical bones was enhanced when the osteocyte network
was disrupted, although the contribution of BCL2 overexpres-
sion in osteoblasts to bone formation could not be completely
excluded (Moriishi et al. 2012). Combining the findings from
these mouse models with the histological observations showing
the inverse linkage between osteocyte density and bone for-
mation, we conclude that the osteocyte network suppresses
bone formation under physiological conditions (Fig. 2).
Fig. 2 Regulation of bone mass by the osteocyte network. a Regula-
tion of bone mass under physiological conditions. The osteocyte net-
work mildly stimulates osteoclastogenesis and bone resorption and
mildly inhibits osteoblast function and bone formation. Rankl expres-
sion in osteoblasts and sclerostin (Sost) expression in osteocytes are, at
least in part, responsible for the enhanced bone resorption and sup-
pressed bone formation, respectively. Both Rankl and osteoprotegerin
(Opg) are highly expressed in osteocytes and Opg seems to be trapped
by Rankl on the surface of osteocytes. sRankl secreted by osteocytes
might be involved in the regulation of osteoclastogenesis (dashed
arrow). b Regulation of bone mass in the unloaded condition. The
osteocyte network strongly stimulates osteoclastogenesis and bone
resorption and strongly inhibits osteoblast function and bone forma-
tion. The osteocyte network enhances Rankl expression in osteoblasts
and Sost expression in osteocytes in the unloaded condition. The
signals from osteocytes that stimulate Rankl expression in osteoblasts
remain to be identified. Upregulation of Rankl in osteocytes in the
unloaded condition is controversial. In a, b, the thickness of the lines
and arrows reflects the strength of the effects and the height of the
osteoblasts reflect their activities
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Sost (sclerostin) is specifically expressed in osteocytes
and inhibits osteoblast function and bone formation by
antagonizing canonical Wnt signaling through binding to
Wnt co-receptor low density lipoprotein receptor-related
protein (LRP) 5 and LRP6, and bone formation is
enhanced in trabecular bone and on the endocortical and
periosteal surfaces of cortical bone in Sost-deficient mice
(Winkler et al. 2003; van Bezooijen et al. 2004, 2007;
Bellido et al. 2005; Li et al. 2005, 2008; Poole et al. 2005;
Semenov et al. 2005). Further, osteocyte-specific deletion of
the parathyroid hormone (PTH) receptor increases Sost expres-
sion and the specific expression of constitutively active PTH
receptor in osteocytes reduces it, indicating the involvement of
Sost in the anabolic action of PTH (Powell et al. 2011; Rhee et
al. 2011). Therefore, Sost is a major negative regulator of
osteoblast differentiation and function produced by osteocytes.
As the dissemination of Sost through canaliculi is impaired in
BCL2 transgenic mice, impaired secretion to the bone surface
should greatly contribute to enhanced bone formation
(Moriishi et al. 2012). However, bone formation is enhanced
in trabecular bone and on the periosteal surface but not on the
endocortical surface of cortical bone in BCL2 transgenic mice
(Moriishi et al. 2012). Thus, the osteocyte network might send
some positive signals to osteoblasts on the endocortical sur-
face, in addition to the negative signal by Sost.
Regulation of bone mass by mechanical stress
Application of mechanical stimuli to osteocytes in vitro
induces the release of anabolic factors, such as prostaglan-
din E2, prostaglandin I2, nitric oxide, cyclooxygenase-2 and
endothelial nitric oxide synthase (Burger and Klein-Nulend
1999). Further, it is widely accepted that mechanical stress
increases bone mass by enhancing bone formation and
inhibiting bone resorption, whereas unloading reduces bone
mass by inhibiting bone formation and enhancing bone
resorption and that the osteocyte network is an appropriate
system for the sensing apparatus (Burger and Klein-Nulend
1999; Martin 2000; Ehrlich and Lanyon 2002; Knothe Tate
2003; Noble 2008; Bonewald and Johnson 2008). However,
difficulties have been experienced in establishing that the
osteocyte network is responsible for the regulation of bone
mass by mechanical stress, because osteocyte death pro-
vokes bone resorption.
Bone-specific Gja1 conditional knockout mice, in which
intercellular communication through gap junctions is dis-
rupted, represent a potential mouse model for evaluating
whether the osteocyte network acts as the mechanosensing
apparatus. However, the responses to mechanical stress in
the Gja1 conditional knockout mice are variable. In the
unloaded condition following hind limb muscle paralysis,
bone resorption is enhanced on the endocortical surface of
tibiae in wild-type mice but not in the conditional Gja1
knockout mice, in which Gja1 is deleted in osteoblasts and
osteocytes using 2.3-kb Col1a1 promoter Cre transgenic mice
(Grimston et al. 2011). However, the finding that bone resorp-
tion on the endocortical surface of the conditional Gja1
knockout mice is enhanced under physiological conditions
makes the evaluation difficult. Two groups have reported the
response to mechanical stress in Gja1 conditional knockout
mice, in which Gja1 is deleted in mature osteoblasts and
osteocytes using human osteocalcin promoter Cre transgenic
mice. Zhang et al. (2011) have shown that periosteal bone
formation is enhanced by mechanical loading in the condi-
tionalGja1 knockout mice but not in wild-type mice, whereas
Lloyd et al. (2012) have demonstrated that bone formation on
both endocortical and periosteal surfaces is decreased in wild-
type mice but not in Gja1 conditional knockout mice at
unloading. As hemichannels and gap junctions, both of which
are formed by Gja1, play important roles in the response to
mechanical stress in osteocytes in vitro (Cherian et al. 2005;
Batra et al. 2012), we need to evaluate the physiological
importance of Gja1 in the response to mechanical stress by
using osteocyte-specific Gja1 conditional knockout mice.
In the unloaded condition, bone resorption is enhanced
and bone formation is mildly suppressed in trabecular bone
of wild-type mice but not of BCL2 transgenic mice at
4 months of age, indicating that the osteocyte network is
responsible for bone loss at unloading (Moriishi et al. 2012).
Rankl is upregulated in osteoblasts of wild-type mice but not
of BCL2 transgenic mice at unloading (Moriishi et al. 2012).
Therefore, the osteocyte network is required for the induc-
tion of Rankl in osteoblasts at unloading. Although Rankl
upregulation in osteocytes in the unloaded condition might
increase bone resorption by reducing Opg release from
osteocytes to the bone surface, the upregulation of Rankl
in osteocytes by unloading is inconsistently observed
(Xiong et al. 2011; Moriishi et al. 2012).
The reduction in bone formation in response to unloading
is abrogated in Sost-/- mice and the level of Sost mRNA but
not Sost-positive osteocytes is increased after unloading
(Robling et al. 2008; Lin et al. 2009). Further, the down-
regulation of Sost after loading is dependent on the site in
the tibiae (Moustafa et al. 2011). In hind limb unloading by
tail suspension, Sost-positive cells are regionally increased
in wild-type mice but not in BCL2 transgenic mice at
4 months of age (Moriishi et al. 2012). Therefore, the
osteocyte network is required for the upregulation of Sost
expression at unloading, which is, at least in part, responsi-
ble for the reduction of bone formation in the unloaded
condition.
Many other molecules, including PTH, estrogen receptor
α, androgen receptor, leptin, periostin, β1 integrin and IL-
11, are also involved in the response to mechanical loading
(Price et al. 2011). Loading above physiological conditions
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activates anabolic pathways and suppresses anti-anabolic
pathways for bone formation and makes the overall function
of osteocytes more anabolic. Recently, we have shown that
the mRNA expression of pyruvate dehydrogenase kinase 4
(Pdk4), which inactivates the pyruvate dehydrogenase com-
plex, is upregulated in osteoblasts and osteocytes in the
unloaded condition in wild-type mice but not in BCL2
transgenic mice at 4 months of age and that bone resorption
is not enhanced in the unloaded condition in Pdk4-deficient
mice. Thus, Pdk4 is involved in a catabolic pathway in the
unloaded condition (Wang et al. 2012).
Concluding remarks
Gene targeting experiments, especially the generation of
osteocyte-specific conditional knockout mice, are revealing
the importance of osteocytes in bone modeling and remodel-
ing. Although these experiments have uncovered the function
of individual genes in osteocytes, the overall function of the
osteocyte network remains to be clarified, because osteocyte
death causes apoptosis- or necrosis-induced bone resorption.
Indeed, an ideal mouse model for the evaluation of the overall
function of the osteocyte network seems to be an impossibil-
ity. Taking into consideration recent findings from osteocyte-
network-disrupted mouse models with previous histological
observations, however, the overall functions of the osteocyte
network are now evident. The osteocyte network enhances
bone resorption by activating osteoclastogenesis but inhibits
bone formation by suppressing osteoblast function under
physiological conditions. In the unloaded condition, the func-
tions of the osteocyte network are augmented and bone
resorption is further enhanced and bone formation is further
inhibited. These functions of the osteocyte network also
explain the increases in bone mass seen after exercise in
many clinical studies (Schwab and Klein 2008), because
the osteocyte network decreases the inhibitory effects on bone
mass by reducing the stimulatory effect on osteoclastogenesis
and the inhibitory effect on osteoblast function in the loaded
condition (under physiological conditions) compared with the
unloaded condition.
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